This year sees the launch of the inaugural CX Innovation Showcase, which will run throughout the meeting. The event showcases the innovation of small, independent and emerging companies in the vascular and endovascular sector. Some of these companies, from the UK, Europe and the US, will be exhibiting in the Registration area and are well worth a visit.
The Showcase culminates in the exciting Innovation Showcase Forum on Tuesday 6th of April, which runs in a Plenary session from 8.00 to 10.45 in the Great Hall, and from 11.15 to 16.30 in the Read lecture hall. The forum will showcase emerging technologies through a series of presentations by a world-class faculty, with each participating company invited to make a presentation on their innovative approach to vascular and endovascular therapies.
Innovation Forum participant companies
IDev
An Innovator and Developer of next generation medical devices for use in the interventional radiology, vascular surgery and cardiology device marketplace. IDev's first tier of products includes the AKónya Eliminator™ Mechanical Thrombectomy Device and the Texan™ Foreign Body Retrieval Device. The SureSave™ Biliary Stent and Precision™ Stent-Delivery Catheter are expected to launch Q3 of the year.
For more information
www.idevtechnologies.com
Lombard Medical
Lombard Medical currently has two products: The AorfixTM uni-iliac AAA stent graft has indicated, through clinical use, to be effective in highly angulated and tortuous anatomies. A bifurcated version has almost completed clinical trials. The repositionable Anson RefixTM vascular clip is successfully in clinical use
www.lombardmedical.com
NovoStent
NovoStent has a ground-breaking radial anchor and helical body stent technology, a paradigm shift fusing the best attributes of balloon expandable and self-expanding stents. NovoStent technology enables application specific solutions not only for mature but also for emerging indications.
Interest contact Michael Hogendijk, President
mhogendijk@novostent.com
ORI Technologies
Our technology brings Engineering Science into the design and functionality of Endovascular grafts. Origami generates a set of patterns which by folding provides a uniform collapsible and expandable structure. Technology advantages include: geometric simplicity, more reliable expansion mechanism, high radial strength, structural shaping and creation of side branches
A member of Isis Innovation, The technology transfer company of the Univ of Oxford
www.isis-innovation.com
UCL Biomedica
Biomaterial & Tissue Engineering group, Royal Free Campus, UCL has developed and patented polymer based on nanocages. It has been extruded as lower limb and coronary artery bypass grafts. Anti-platelet and anti-coagulant peptides are attached via a spacer arm technology. The grafts are undergoing in vivo tests and it is aim for a clinical trial within 18 months.
Interest contact Dr Seifalian
a.seifalian@rfc.ucl.ac.uk
Veryan Medical
Veryan Medical Ltd is developing a range of proprietary vascular devices to reduce associated intimal hyperplasia by optimising device haemodynamics. The first product, SwirlGraftTM, will enter clinical trials for AV access and peripheral bypass applications during 2004, followed by the SwirlSheathTM external stent graft and the SwirlFlowTM endovascular stent
For more details see
www.veryanmed.com
Invatec
Since its foundation in 1996, one of Invatec's well proven strengths has been the ability to focus on customer needs, before market needs and the capacity of fast time to market and turn to their customers needs and ideas into concrete products in a fast and effective fashion. Inside its entire and ever expanding coronary and vascular product portfolios, MO.MA, the unique proximal flow blockage cerebral protection device, represents a clear example of the Company's commitment in this direction.
For more details see
www.invatec.it
